Genome & Company (KOSDAQ:314130) Stock Catapults 39% Though Its Price And Business Still Lag The Industry
Genome & Company (KOSDAQ:314130) shares have continued their recent momentum with a 39% gain in the last month alone. The annual gain comes to 217% following the latest surge, making investors sit up and take notice.
Although its price has surged higher, Genome may still be sending buy signals at present with its price-to-sales (or “P/S”) ratio of 11.8x, considering almost half of all companies in the Biotechs industry in Korea have P/S ratios greater than 15.8x and even P/S higher than 93x aren’t out of the ordinary. Although, it’s not wise to just take the P/S at face value as there may be an explanation why it’s limited.
